November 2022

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences

press releases /

Press Release TEL AVIV, Israel & MELBOURNE, Australia, November 21, 2022 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that members of management will present at BTIG’s Ophthalmology Day 2022, being held on November 29, and at the Piper Sandler 34th […]

Azura Ophthalmics Announces Participation at Upcoming Investor Conferences Read More »

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

press releases /

Press Release — AZR-MD-001 0.5% meets co-primary efficacy endpoints, making it the first investigational drug to show significant improvements in both signs and symptoms of Meibomian Gland Dysfunction — — Restoration of gland function shown to improve downstream response measures of ocular conditions associated with Meibomian Gland Dysfunction — — Rapidly advancing AZR-MD-001 to Phase

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction Read More »

Scroll to Top